MyFamily First Technologies
Roche purchased similar capabilities for $200M - Bloodhound. Our ‘Puppy’ has been vetted by a global leader and the first right of refusal has been purchased.
Rapid evaluation of patients will lower the overall healthcare delivery cost, provide greater independence for age-related diseases, and promotes active lifestyles. In 2013 Roche invested $200M in the Bloodhound prototype for hospital blood diagnostics. MyFamily First Technologies advanced those capabilities, now offering point-of-care testing (POCT) at a disruptively low cost/high margin, nicknamed the Puppy. All from a single finger stick.